We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Immunexpress Awarded Grant to Bring Sepsis MDx Assay to Market
News

Immunexpress Awarded Grant to Bring Sepsis MDx Assay to Market

Immunexpress Awarded Grant to Bring Sepsis MDx Assay to Market
News

Immunexpress Awarded Grant to Bring Sepsis MDx Assay to Market

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Immunexpress Awarded Grant to Bring Sepsis MDx Assay to Market"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Immunexpress Group announce it has received Early Stage Commercialisation support through Commercialisation Australia, an initiative of the Australian Government. The AUD $982,707 grant will support the company’s AUD 2.2 million project, intended to bring the Immunexpress innovative whole blood qRT-PCR diagnostic assay (SeptiCyte® PLUS) to market. SeptiCyte® PLUS is designed to diagnose sepsis accurately within a clinically relevant timeframe.

“This is an important step forward in the development of SeptiCyte® PLUS and our efforts to bring novel sepsis assays to health care centers and patients around the world,” said Dr Roslyn Brandon, President and Chief Executive Officer, Immunexpress. “Based on the results to date, SeptiCyte® PLUS has the potential to make an important impact on the health care community and improve patient outcomes by allowing for earlier diagnosis and targeted antimicrobial treatment within a clinically relevant time frame of under three hours.“

The grant funding, along with existing cash resources, will be used to develop the SeptiCyte® PLUS prototype through to a Laboratory Developed Test (LDT), and make it available to hospital labs at two large health systems in the U.S. along with one major academic hospital in Germany. The prospective data collected through these centers is expected to inform the regulatory pathway and future medical device application for SeptiCyte® PLUS in the U.S.

New technologies that allow for the earlier detection and personalized management of people with, or at risk of, sepsis could significantly reduce the financial burden on health care systems worldwide through reduced patient mortality and morbidity; reduced stays in hospital and intensive care units (ICUs); more targeted use of antibiotics and anti-inflammatories; and reduced antimicrobial resistance.
Advertisement